TICKERNERD
Menu
HSCSHSCSHealthcare · Medical Devices

HSCS Stock Forecast: HeartSciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.04
−12.89% on the day

The 1 Wall Street analysts covering HeartSciences, Inc. hold a median 12-month price target of $12 — +294.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$16.9M
Ticker Nerd rank
48 / 100
Median analyst target
$12
Analysts covering
1
Revenue$0.0−100.0% y/y
Operating income−$2.5M
Net income−$2.8M
Free cash flow−$1.7M
Quarterly, 8 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−21.9%
1M
−25.5%
YTD
−1.6%
1Y
−18.3%
From 52W high
−41.5%
From 52W low
+82.0%
$1.67
$5.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HSCS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Size
90
Revisions
79
Momentum
69
Volatility
66
Growth
39
Value
11
Quality
5
Issuance
3

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HSCS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HSCS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26HSCSHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +294.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Mar 2026Ascendiant CapitalMaintainsBuy$9.20 → $8.00
22 Dec 2025Ascendiant CapitalMaintainsBuy—
1 Oct 2025Ascendiant CapitalMaintainsBuy—
18 Mar 2025Ascendiant CapitalMaintainsBuy—
18 Dec 2024Maxim GroupReiteratesBuy—
23 Sept 2024Ascendiant CapitalReiteratesBuy—
30 Jan 2023Ascendiant CapitalInitiatesBuy—
19 Dec 2022Maxim GroupMaintainsBuy—
9 Nov 2022Maxim GroupInitiatesBuy—
8 Aug 2022BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HSCS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HSCS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, HeartSciences, Inc. returned −18.3% against +16.2% for the S&P 500, dividends included.

HSCS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26HSCSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HSCS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

HeartSciences, Inc. (HSCS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 71% of US stocks

Price / sales
3740.9×

Cheaper than 1% of US stocks

Price / book
61.4×

Cheaper than 2% of US stocks

EV / EBITDA
−2.2×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
10.5%

Higher than 53% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−139956.7%

Higher than 1% of US stocks

Net margin
59.1%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−1851.9%

Higher than 1% of US stocks

Return on assets
−116.4%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HeartSciences, Inc. (HSCS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HeartSciences, Inc. has a market value of $16.9M and an enterprise value of $20.7M.

  • Revenue in the twelve months to 30 Apr 2026: $4K. The latest quarter grew 10.5% year on year.

  • Net income over the same four quarters: −$9.1M, a −211666.5% net margin.

  • Free cash flow in the twelve months to 30 Apr 2026: −$7.5M.

  • Shares outstanding: 3.2M.

  • Trailing P/E: 0.5×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • HeartSciences, Inc. employs 14 people — $308.5 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

HSCS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HSCSHeartSciences, Inc.$16.9M
48
IRIXIRIDEX Corp.$15.4M
81
SINTSINTX Technologies, Inc.$13.4M
28
PLSMPulsenmore Ltd.$13.3M
34
LFWDLifeward Ltd.$18.1M
24
CTSOCytoSorbents Corp.$11.8M
45
PAVMPAVmed, Inc.$21.5M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HSCS news & analysis

HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device

GlobeNewsWire · 6 Oct 2026positive

HeartSciences announced that the FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers ECG signal acquisition and interpretation for adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements provided to clinicians on an advisory basis.

Why it matters — The clearance is a regulatory milestone for HSCS’s MyoVista wavECG device and specifies its permitted patient settings and advisory interpretation use.

Fortitude Appoints Kimberly Pittman as Chief Legal Officer

Business Wire · 29 Sept 2026neutral

Fortitude Mining Holdings announced the appointment of Kimberly Pittman as Chief Legal Officer, effective September 28. Pittman joins Fortitude's executive leadership team as the company prepares for its previously announced proposed business combination with HeartSciences Inc. (Nasdaq: HSCS).

Why it matters — HSCS watchers would care because Pittman's appointment signals Fortitude is advancing its executive leadership in preparation for the proposed business combination with HeartSciences.

HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

GlobeNewsWire · 15 Sept 2026neutral

HeartSciences reported its fiscal first quarter 2027 financial results and provided a business update. The company noted that its proposed business combination with Fortitude, a Zcash-anchored digital asset mining platform, continues to progress with closing expected in Q4 calendar 2026.

Why it matters — HSCS watchers would want to track the timeline and progress of the proposed Fortitude business combination, which is expected to close in Q4 calendar 2026.

HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Sept 2026negative

HeartSciences Inc. (HSCS) reported a quarterly loss of $0.86 per share, which was wider than the Zacks Consensus Estimate of a $0.78 loss but narrower than the $1.58 per-share loss reported a year ago.

Why it matters — The company's quarterly loss missed analyst estimates, even as it marked an improvement over the prior-year period, making the report relevant for investors tracking HSCS's earnings performance.

Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration

GlobeNewsWire · 19 Aug 2026positive

Fortitude Mining Holdings purchased 411,522 shares of HeartSciences common stock in a private placement for approximately $1.0 million at $2.43 per share, a 22% premium to the closing price on the purchase date. The merger exchange ratio remains unchanged, with no additional shares to be issued at closing, and Fortitude now holds approximately 9.4% of HeartSciences' outstanding shares.

Why it matters — A $1.0 million investment at a 22% premium from the counterparty in the pending merger, with Fortitude's stake reaching about 9.4%, signals increased alignment between HeartSciences and its merger partner without diluting existing merger consideration.

FAQ

Frequently asked questions about HSCS stock

What is the HSCS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering HeartSciences, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HSCS stock a buy right now?

Of the 1 analysts covering HeartSciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartSciences, Inc. 48 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HSCS?

As at 8 Oct 2026, HeartSciences, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will HSCS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +294.7% from the last close, and Ticker Nerd's factor model ranks HeartSciences, Inc. 48 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HSCS stock forecast for 2030?

No analyst covering HeartSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has HSCS stock performed over the past year?

HeartSciences, Inc. returned -18.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartSciences, Inc. do?

HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography.

What is the latest news on HSCS?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device". HeartSciences announced that the FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers ECG signal acquisition and interpretation for adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements provided to clinicians on an advisory basis.

Company

About HeartSciences, Inc.

HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography. The company develops AI-ECG solutions designed to improve the clinical usefulness of standard ECG testing by helping detect cardiac dysfunction and related heart conditions earlier in care pathways. Its current product set includes the MyoVista wavECG device, a resting 12-lead ECG that combines conventional rhythm and diagnostic information in a single test, and MyoVista Insights, a cloud-native ECG management platform that is designed to work across different device and vendor environments. HeartSciences serves healthcare settings where rapid cardiac screening and interpretation are important, including frontline and point-of-care environments. Founded in 2007 and headquartered in Southlake, Texas, the company positions itself within the healthcare information technology and medical devices market, with a focus on practical ECG enhancement rather than replacing existing clinical workflows.

CEO Mr. Andrew Simpson · 14 employees · United States · https://heartsciences.com